Ixazomib is a proteasome inhibitor classified as an antineoplastic agent, approved for use in combination with lenalidomide and dexamethasone to treat multiple myeloma in adults who have received at least… Read more






![Chemical structure of 2,5-Dichloro-N-(2-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-2-oxoethyl)benzamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1201903-02-7-25-Dichloro-N-2-R-3-methyl-1-3aS4S6S7aR-3a55-trimethylhexahydro-46-methanobenzod132dioxaborol-2-ylbutylamino-2-oxoethylbenzamide.png&w=3840&q=75)
































Ixazomib is a proteasome inhibitor classified as an antineoplastic agent, approved for use in combination with lenalidomide and dexamethasone to treat multiple myeloma in adults who have received at least one prior therapy. Analytical laboratories rely on high-quality reference standards for this active pharmaceutical ingredient to support rigorous quality control and method validation protocols. This category encompasses a comprehensive collection of related compounds, including synthetic impurities, degradation products, and trimer forms, which are essential for impurity profiling during stability studies. Furthermore, stable isotope labelled compounds are available to serve as precise internal standards for mass spectrometry-based bioanalytical assays. By utilizing these characterized materials, pharmaceutical researchers can accurately monitor process consistency and ensure the safety and efficacy of final drug formulations throughout the product lifecycle.